GLP-1 Drugs and Longevity: The 20% Heart Attack Reduction and What Else They Do for Aging Men

The SELECT trial enrolled men and women who were overweight or obese and had a history of cardiovascular disease but did NOT have type 2 diabetes. That last part is critical — it means the benefit wasn't just about blood sugar. Over 34 months, semaglutide 2.4mg cut major adverse cardiac events (MACE) by 20% compared to placebo. The absolute risk reduction was 1.5 percentage points, which sounds small until you calculate how many people that represents across a population. For a drug already being taken by millions of men, that's a meaningful longevity intervention. The mechanism isn't just weight loss. GLP-1 receptors sit directly on heart muscle cells and on the lining of blood vessels. The drug appears to reduce inflammation in coronary arteries, improve how the heart uses glucose during stress, and lower blood pressure by about 4-6 points. Weight loss helps too, obviously — but the cardiac benefit in SELECT appeared earlier than weight loss alone would explain. Something else is going on at the tissue level.

Most men don't think about their liver unless something goes very wrong. But fatty liver disease — technically called NASH (non-alcoholic steatohepatitis) or hepatic steatosis — is one of the most underrecognized drivers of accelerated aging in men over 40. Fat accumulates in liver cells, which triggers low-grade inflammation throughout the body, drives insulin resistance, and makes every metabolic process less efficient. GLP-1 drugs reduce liver fat. Multiple trials show meaningful reductions in hepatic steatosis and inflammation markers in men taking semaglutide or tirzepatide. This matters because liver fat doesn't just affect the liver — it amplifies the chronic inflammation that researchers now think is the dominant mechanism behind aging-related disease. They even have a word for it: inflammaging. Less liver fat means lower baseline inflammation, better insulin sensitivity, and a metabolic environment where your hormones actually work properly. GLP-1's effect on the liver may be just as important as its effect on the heart — it just hasn't had its SELECT trial moment yet.

GLP-1 receptors exist throughout the brain — including in the exact regions that are damaged in Parkinson's and Alzheimer's disease. Animal studies show GLP-1 drugs reduce the sticky protein plaques associated with Alzheimer's and slow tau tangles. Phase III human trials for Parkinson's disease are currently underway. This isn't fringe science — it's serious enough that major neurology research centers are running formal trials. The sleep connection is also clinically real. The SURMOUNT-OSA trial in 2024 showed tirzepatide producing a 30-40% reduction in sleep apnea severity, with 51% of participants achieving full resolution. Sleep apnea matters for aging men for a very specific reason: each apnea event wakes your stress system at night, suppressing the slow-wave sleep phases where your body produces the majority of its testosterone. Fix the sleep apnea, restore deep sleep, and you recover some of the testosterone loss that most men attribute entirely to age. GLP-1 drugs may be doing meaningful longevity work in the brain and while you sleep — not just in the cardiovascular system.

Here's the honest downside for men over 50: GLP-1 drugs cause lean mass loss alongside fat loss. In trials, roughly 25-40% of weight lost on GLP-1s comes from lean tissue rather than fat. For men over 50 who are already losing 1-2% of muscle mass per year naturally, this is a real concern, not a footnote. Muscle mass is one of the strongest predictors of longevity in men. It protects joints, supports metabolic rate, reduces fall risk, and correlates with longer survival independent of almost everything else. If GLP-1 therapy is stripping away the very tissue that predicts your longevity, the drug's benefits come with a cost. The mitigation is well-established: resistance training, protein targets around 1.6g per kilogram of body weight daily, creatine monohydrate at 5g/day, and essential amino acid supplementation. These aren't optional additions if you're on a GLP-1 drug at 50+. They're what separates the longevity benefit from the longevity risk. Done right, GLP-1 plus structured resistance training produces a body composition outcome far better than either alone.